icon

$0 Co-Pay Program

Rubraca is available at $0 co-pay to 100% of commercially insured patients, regardless of income.

icon

Text-based support

The Clovis4YOU text message support program is a personalized patient program with medication reminders, daily tips, emotional support, and more that can help you throughout treatment.

icon

Share Your Story

You can make a difference for yourself and others by sharing your experiences and perspective.

Resources for men taking Rubraca

Here are tools to download, and a list of prostate cancer organizations you can access to support yourself, family members, and care partners

Brochure imageBrochure image

Take the Patient Brochure with you. It has even more information on how Rubraca might be right for you.

Download the Patient Brochureicon
Assistance program
DO YOU KNOW
YOUR BRCA STATUS?
Download the BRCA Fact Sheet

Organizations supporting men, family members, and care partners impacted by BRCA+ metastatic castration-resistant prostate cancer

American Cancer Society

Funds and conducts research, shares information from experts, supports patients.

visit
CancerCare

Provides telephone, online, and face-to-face counseling, support groups, education, publications, and financial assistance.

visit
Fans for the Cure

Fans for the Cure (FFTC) is a nonprofit organization that seeks to promote men’s health by advocating for the early detection of prostate cancer and best practices in the treatment of the disease. 

visit
FORCE: Facing Hereditary Cancer EMPOWERED

Provides education, advocacy, and research specific to hereditary cancer.

visit
Malecare

Malecare is America’s leading men’s cancer survivor support and advocacy national nonprofit organization.

visit
Men's Health Network

Men's Health Network (MHN) is a national nonprofit organization whose mission is to reach men, boys, and their families where they live, work, play, and pray with health awareness and disease prevention messages and tools, and screening programs.

visit
National Cancer Institute

Leads, conducts, and supports cancer research to advance scientific knowledge and help all people live longer, healthier lives. The National Cancer Institute (NCI) is the federal government's principal agency for cancer research and training.

visit
OncoLink

Provides web-based patient and professional oncology education designed to be a one-stop shop.

visit
Prostate Cancer Foundation

PCF funds the world’s most promising research to improve the prevention, detection, and treatment of prostate cancer and ultimately cure it for good.

visit
Prostate Cancer Research Institute

The Prostate Cancer Research Institute's mission is to improve the quality of prostate cancer patients’ and caregivers’ lives by supporting research and disseminating information that educates and empowers patients, families, and the medical community.

visit
Prostate Conditions Education Council (PCEC)

As the leading innovative organization saving and improving the lives of men and their loved ones, we set the pace in early detection, research, education and awareness for prostate cancer and all prostate conditions.

visit
Prostate Health Educaton Network (PHEN)

PHEN's mission is to eliminate the African American prostate cancer disparity, but also includes advocacy efforts to increase the overall support and resources for a war on prostate cancer that will lead to a cure for the disease for the benefit of all men. 

visit
Us TOO

To raise awareness and provide educational resources and support services to those affected by prostate cancer to help them learn to fight this disease. The power of Us TOO is in helping men and those who love them by transforming resignation into determination and fear into hope.

visit
ZERO — The End of Prostate Cancer

ZERO — The End of Prostate Cancer is the leading national nonprofit with the mission to end prostate cancer. ZERO advances research, improves the lives of men and families, and inspires action.

visit

You are now leaving the Rubraca.com website.

The link you have selected will take you to a third-party site. Clovis Oncology is not responsible for the content on third-party sites. You are encouraged to read the Terms and Conditions and Privacy Policy of the third-party site.

Click CANCEL to return to Rubraca.com. To proceed, click CONTINUE.

Assistance program
Get personalized assistance with
a text-based support program
Enroll in Clovis4YOU today

Glossary

Antiemetics/antinausea medication: drugs taken to prevent or treat nausea and vomiting.
BRCA: stands for BReast CAncer susceptibility gene.
BRCA+: term used to describe a patient who has a BRCA gene mutation.
BRCA mutation: a break in the BRCA1 or BRCA2 gene that normally aids in repairing cell DNA damage; BRCA gene mutations can be inherited (germline) or acquired spontaneously (somatic).
Castration-resistant prostate cancer: prostate cancer that no longer responds to drug or surgical treatments to lower testosterone.
Chemotherapy: a type of cancer treatment that uses drugs to eliminate cancer cells. Rubraca is approved for patients following the use of a taxane-based chemotherapy which is commonly given through a slow injection into a vein.
Clinical study: research that is designed to test new medical approaches, such as new medicines, and find out if they work and are safe for people.
DNA (deoxyribonucleic acid): molecules that tell your cells how to survive and grow.
Disease progression: cancer that continues to grow or spread.
Genes: a set of coded instructions in cells for making new proteins and controlling how cells behave.
Germline BRCA mutation: also called an inherited mutation, meaning the gene mutation is passed down from parent to child. Germline mutations are present in every cell in the body, not just in the tumor cells.
mCRPC (metastatic castration-resistant prostate cancer): prostate cancer that has spread to other parts of the body and that no longer responds to drug or surgical treatments to lower testosterone.
Metastatic prostate cancer: prostate cancer that has spread to other parts of the body.
Mutation: a change in the DNA sequence.
PARP: poly (ADP-ribose) polymerase, a protein that helps cells repair their DNA when it has been damaged (ie, by chemotherapy or your body’s own immune system).
PARP inhibitor (PARPi) (poly (ADP-ribose) polymerase inhibitor): a medicine that blocks PARP in cancer cells to prevent DNA repair and cause them to die. PARP inhibitors may also impact other cells and tissues.
Placebo: a substance that does not contain any active medication.
Response: therapeutic effect of treatment.
Side effect: a problem that may occur when treatment affects healthy tissues or organs.
Somatic BRCA mutation: also called an acquired mutation, meaning the gene mutation is not passed down from parent to child, but occurs randomly and can develop at any time. Somatic mutations are only present in the tumor cells.

What is Rubraca used for?

Rubraca® (rucaparib) tablets are a prescription medicine used in adults for the treatment of castration-resistant prostate cancer (prostate cancer that no longer responds to medical or surgical treatment that lowers testosterone):

  • that has spread to other parts of the body, and
  • has a certain type of inherited (germline) or acquired (somatic) abnormal BRCA gene, and you have been treated with certain medicines for your cancer.

Rubraca was approved based on response rate and how long patients’ responses lasted. There are ongoing studies to confirm the clinical benefit of Rubraca. Your healthcare provider will perform a test to make sure Rubraca is right for you.

It is not known if Rubraca is safe and effective in children.

What Warnings should I know about Rubraca?

Rubraca tablets may cause serious side effects including bone marrow problems called Myelodysplastic Syndrome (MDS) or a type of cancer of the blood called Acute Myeloid Leukemia (AML). Some people who have ovarian cancer and who have received previous treatment with chemotherapy or certain other medicines for their cancer have developed MDS or AML during or after treatment with Rubraca, although MDS or AML was not observed in men with prostate cancer during the clinical study. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with Rubraca.

If you are a male with a female partner who is pregnant or able to become pregnant, effective birth control should be used during treatment and for 3 months after the last dose of Rubraca. Do not donate sperm during use and for 3 months after the last dose of Rubraca.

What other important information should I know about Rubraca?

Your healthcare provider will do blood tests before, and every month during treatment with Rubraca to monitor your blood cell counts. Weekly blood tests will be performed if you have low blood cell counts for a long time. Your healthcare provider may stop treatment with Rubraca until your blood cell counts improve.

Avoid spending time in sunlight while on Rubraca since your skin may become more sensitive to the sun and may sunburn more easily. You should wear a hat and clothes that cover your skin and use sunscreen to help protect against sunburn if you have to be in the sunlight.

What are the side effects of Rubraca?

The most common side effects for men in Rubraca clinical studies were weakness/fatigue, nausea, decreased red blood cell count, changes in liver function tests, decreased appetite, constipation, rash, decreased platelet count, vomiting, and diarrhea.

What other medications might interact with Rubraca?

Rubraca can increase the amounts of other medications you may be taking which can increase the risk of side effects. Tell your healthcare provider about all of your medical conditions and all medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

You may report side effects to the FDA at 1‑800‑FDA‑1088 or www.fda.gov/medwatch. You may also report side effects to Clovis Oncology, Inc. at 1‑415‑409‑7220 (US toll) or 1‑844‑CLVS‑ONC (1‑844‑258‑7662; US toll-free).

Please see full Prescribing Information, including Patient Information, for additional Important Safety Information.